{"id":"https://openalex.org/W2590532786","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.2060","title":"A phase II trial of PTK-787 (PTK/ZK) in recurrent or progressive meningiomas","display_name":"A phase II trial of PTK-787 (PTK/ZK) in recurrent or progressive meningiomas","publication_year":2008,"publication_date":"2008-05-20","ids":{"openalex":"https://openalex.org/W2590532786","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.2060","mag":"2590532786"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2008.26.15_suppl.2060","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.2060","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2008.26.15_suppl.2060","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5042283383","display_name":"Rebecca Jane DeBoer","orcid":"https://orcid.org/0000-0001-8083-1290","observed_orcids":["https://orcid.org/0000-0001-8083-1290"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. DeBoer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041824343","display_name":"Sean Aaron Grimm","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. A. Grimm","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"J. Chandler","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Chandler","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085622725","display_name":"Lilia Gallot","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L. Gallot","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006937551","display_name":"Sean Kennedy","orcid":"https://orcid.org/0000-0003-0855-166X","observed_orcids":["https://orcid.org/0000-0003-0855-166X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. Kennedy","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"K. Burns","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K. Burns","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"L. Rice","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L. Rice","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022097433","display_name":"C. Cabreza","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Cabreza","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073330859","display_name":"Kei Muro","orcid":"https://orcid.org/0000-0002-5572-743X","observed_orcids":["https://orcid.org/0000-0002-5572-743X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K. Muro","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5029952866","display_name":"Jeffrey J. Raizer","orcid":"https://orcid.org/0009-0003-8469-2509","observed_orcids":["https://orcid.org/0009-0003-8469-2509"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. J. Raizer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":8,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"26","issue":"15_suppl","first_page":"2060","last_page":"2060"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11251","display_name":"Meningioma and schwannoma management","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11251","display_name":"Meningioma and schwannoma management","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12622","display_name":"Neurosurgical Procedures and Complications","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10975","display_name":"Bone Tumor Diagnosis and Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/recurrent-meningioma","display_name":"recurrent meningioma","score":0.656000018119812},{"id":"https://openalex.org/keywords/hemangiopericytoma","display_name":"hemangiopericytoma","score":0.9750000238418579},{"id":"https://openalex.org/keywords/vegfr-tyrosine-kinase-inhibitors","display_name":"VEGFR inhibitors","score":0.8930000066757202},{"id":"https://openalex.org/keywords/oral-tyrosine-kinase-inhibitor","display_name":"oral tyrosine kinase inhibitor","score":0.8510000109672546},{"id":"https://openalex.org/keywords/angiogenesis-inhibition","display_name":"angiogenesis inhibition","score":0.7620000243186951},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8650000095367432},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.6909999847412109},{"id":"https://openalex.org/keywords/drug-toxicity","display_name":"drug toxicity","score":0.5830000042915344},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.781000018119812},{"id":"https://openalex.org/keywords/radiological-response","display_name":"radiological response","score":0.6480000019073486},{"id":"https://openalex.org/keywords/egfr","display_name":"EGFR","score":0.4699999988079071},{"id":"https://openalex.org/keywords/her2","display_name":"HER2","score":0.9309999942779541}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9068562388420105},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.6338950991630554},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.6257200241088867},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.574667751789093},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.5367931127548218},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.5124121308326721},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.49505415558815},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.4476340711116791},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.39708828926086426},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.35594892501831055},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3527255058288574},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.26503825187683105}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2008.26.15_suppl.2060","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.2060","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2008.26.15_suppl.2060","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2585431017","https://openalex.org/W2074400892","https://openalex.org/W2965697431","https://openalex.org/W3009465108","https://openalex.org/W2027675488","https://openalex.org/W2767061846","https://openalex.org/W2332800771","https://openalex.org/W2051429797","https://openalex.org/W1995312162","https://openalex.org/W2804215377"],"abstract_inverted_index":{"2060":[0],"Background:":[1],"Treatment":[2,143],"options":[3],"are":[4],"limited":[5],"for":[6,145,271],"patients":[7,69],"(pts)":[8],"with":[9,46,70,206,331],"recurrent":[10,47,332],"meningiomas.":[11,335,366],"VEGF":[12,27],"and":[13,17,28,64,93,116,158,161,178,239,267,292,300,353],"PDGF":[14,29],"promote":[15],"angiogenesis":[16],"cellular":[18],"proliferation.":[19],"PTK-787":[20,43,109,336],"is":[21,165,202,319,337,349],"an":[22],"orally":[23],"active":[24],"inhibitor":[25,328],"of":[26,34,42,88,104,125,153,169,198,344],"receptors.":[30],"The":[31],"primary":[32],"endpoint":[33],"this":[35,359],"trial":[36,322],"was":[37,107,138,191,216,251,281,298,305],"to":[38,122,200,242,247,253,262,265,303,323],"determine":[39],"the":[40,276,311,320],"efficacy":[41],"in":[44,163,226,275,284,289,294,329,365],"pts":[45,172,208,219,258,280,314,330],"or":[48,77,79,148,333,375,378],"progressive":[49,89,334],"meningiomas":[50,73],"as":[51],"noted":[52],"by":[53,118],"radiographic":[54],"response.":[55,272],"Main":[56],"secondary":[57],"endpoints":[58],"were":[59,81,130,259,268,356],"6-month":[60],"progression-free":[61],"survival":[62],"(PFS-6)":[63],"overall":[65],"survival.":[66],"Methods:":[67],"Adult":[68],"histologically":[71],"proven":[72],"(grade":[74],"I,":[75],"II,":[76],"III)":[78],"hemangiopericytomas":[80],"eligible.":[82],"Pts":[83],"must":[84],"have":[85,173],"a":[86,123,325,341],"history":[87],"disease,":[90],"KPS":[91],"\u226560,":[92],"not":[94,269],"be":[95,363,370],"on":[96,102,210],"enzyme":[97],"inducing":[98],"anti-convulsants.":[99],"No":[100,212],"limit":[101],"number":[103,197],"prior":[105,264],"therapies":[106],"placed.":[108],"administration":[110],"began":[111],"at":[112,340],"250":[113,119],"mg":[114,127,249,255],"BID":[115,250],"increased":[117],"mg/day":[120],"weekly":[121],"dose":[124,245,343],"500":[126,254],"BID.":[128,256],"Exams":[129],"done":[131,139],"after":[132],"each":[133],"4-week":[134],"treatment":[135],"cycle;":[136],"imaging":[137,266],"every":[140],"8":[141],"weeks.":[142],"continued":[144],"12":[146],"months":[147],"until":[149],"disease":[150,288,351],"progression.":[151],"Evaluation":[152],"VEGF,":[154],"EGFR,":[155],"PDGF,":[156],"HER2,":[157],"ET":[159],"1":[160,183,285],"2":[162],"tissue":[164],"planned.":[166],"Results:":[167],"13":[168],"planned":[170],"25":[171],"enrolled:":[174],"6":[175,179,187],"grade":[176,180,213,224,230],"II":[177],"III":[181],"meningiomas,":[182],"hemangiopericytoma":[184],"(7":[185],"men;":[186],"women).":[188],"Median":[189,196],"age":[190],"60":[192],"years":[193],"(range":[194,204,308],"30\u201389).":[195],"cycles":[199],"date":[201],"4":[203,207,214],"1.5\u20139.4)":[205],"still":[209],"treatment.":[211],"toxicity":[215],"observed.":[217],"All":[218],"experienced":[220],"fatigue,":[221],"which":[222],"reached":[223],"3":[225,227,231],"pts.":[228],"Other":[229,387],"toxicities:":[232],"jaw":[233],"pain,":[234],"elevated":[235],"transaminases,":[236],"anorexia,":[237],"rash,":[238],"hypertension.":[240],"Due":[241],"intolerability,":[243],"original":[244],"escalation":[246],"750":[248],"reduced":[252],"Two":[257],"withdrawn":[260],"due":[261],"rash":[263],"evaluable":[270,279,313],"Best":[273],"response":[274,283],"remaining":[277],"11":[278],"partial":[282],"(8%),":[286],"stable":[287],"9":[290],"(69%),":[291],"progression":[293,304],"1.":[295],"Overall":[296],"PFS-6":[297],"46%":[299],"median":[301],"time":[302],"15.7":[306],"weeks":[307],"7.6\u201332)":[309],"among":[310],"7":[312],"who":[315],"progressed.":[316],"Conclusions:":[317],"This":[318],"first":[321],"use":[324],"combination":[326],"VEGF/PDGF":[327],"better":[338],"tolerated":[339],"total":[342],"1,000":[345],"mg.":[346],"Although":[347],"data":[348,368],"accumulating,":[350],"stabilization":[352],"minor":[354],"responses":[355],"seen,":[357],"suggesting":[358],"targeted":[360],"approach":[361],"may":[362],"useful":[364],"Updated":[367],"will":[369],"presented.":[371],"Author":[372],"Disclosure":[373],"Employment":[374],"Leadership":[376],"Consultant":[377],"Advisory":[379],"Role":[380],"Stock":[381],"Ownership":[382],"Honoraria":[383],"Research":[384],"Expert":[385],"Testimony":[386],"Remuneration":[388],"Novartis":[389]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2017-03-03T00:00:00"}